Effectiveness and safety of rivaroxaban for anticoagulation therapy in COVID-19: A meta-analysis of randomized...

Area of Science:

• Medical research
• Pharmacology
• Infectious diseases

Background:

• COVID-19 is associated with a high risk of thrombotic events.
• Anticoagulation is a key management strategy for COVID-19 patients.
• Rivaroxaban is an oral anticoagulant with potential use in COVID-19.

Purpose of the Study:

• To evaluate the effectiveness and safety of rivaroxaban for anticoagulation in COVID-19 patients.
• To compare rivaroxaban with other anticoagulants and placebo in randomized controlled trials.

Main Methods:

• Systematic search of PubMed, Embase, Cochrane Library, and ClinicalTrials.gov.
• Inclusion of 6 randomized controlled trials (RCTs) with 3323 patients.
• Data analysis focused on mortality, hospitalization, thrombotic, and bleeding events.

Main Results:

• Rivaroxaban did not significantly reduce all-cause mortality or hospitalization rates.
• Thrombotic events were reduced with rivaroxaban prophylaxis versus placebo.
• No significant difference in thrombotic event reduction between rivaroxaban and heparin/LMWH; potential increase in bleeding risk with rivaroxaban.

Conclusions:

• Rivaroxaban may reduce thrombotic events in COVID-19 but lacks superiority over heparin/LMWH.
• Rivaroxaban use may be associated with an increased risk of bleeding.
• The role of rivaroxaban in COVID-19 anticoagulation requires careful consideration of risks and benefits.